Partnership will leverage Vivtex’s proprietary technologies built to identify optimal oral formulations for peptide and protein therapeutics with improved bioavailabilityNovo Nordisk will lead global development and commercialization, and Vivtex is eligible to receive up to 2.1 billion US dollars, as well as royalties on net sales of future productsPartnership expands Vivtex’s platform to metabolic diseases and supports Novo Nordisk’s mission to deliver scalable and innovative medicines to people with obesi ...

Core Insights - Tempest Therapeutics announced promising clinical data from the ongoing REDEEM-1 Phase 1/2a trial for TPST-2003, a dual-targeting CAR-T therapy for relapsed/refractory multiple myeloma [1][6] Clinical Data Summary - TPST-2003 is designed to enhance response depth and durability in patients with relapsed/refractory multiple myeloma through a dual-targeting CAR structure [2] - As of January 31, 2026, 36 patients with relapsed/refractory multiple myeloma have received TPST-2003, with a median of four prior lines of therapy [3] - All six evaluable patients in the REDEEM-1 trial achieved a complete response (CR), resulting in an overall response rate (ORR) of 100% among 25 evaluable patients [4][8] Safety Profile - TPST-2003 demonstrated a favorable safety profile across all dose levels, with no Grade >3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) reported [7][9] - The prior investigator-initiated trial (IIT) showed a median progression-free survival (PFS) of 23.1 months, including patients with extramedullary disease [8][10] Future Development Plans - Tempest plans to accelerate the development of TPST-2003 and intends to submit a U.S. IND application, aiming to initiate a U.S. registrational study in 2026 [6][15] - The company is also exploring the potential of TPST-2003 for treating large B-cell lymphoma and other related indications [6][12] Treatment Landscape - Approved CAR-T therapies have shown clinical benefits in relapsed/refractory multiple myeloma, but challenges such as relapse and toxicity management remain prevalent [13] - TPST-2003's dual-targeting CAR structure aims to address tumor heterogeneity and antigen escape, which are significant factors in disease progression [14]

Core Viewpoint - Ryman Hospitality Properties, Inc. plans to offer $700 million in senior notes due 2034 to refinance existing debt and strengthen its financial position [1][2]. Group 1: Offering Details - The company intends to issue $700 million in senior unsecured notes, which will be guaranteed by the company and its subsidiaries [1]. - The net proceeds from the offering will be used to fully redeem the existing 4.750% senior notes due 2027, including accrued interest and related fees [2]. Group 2: Regulatory Compliance - The notes will be offered only to qualified institutional buyers and certain non-U.S. persons, in compliance with Rule 144A and Regulation S under the Securities Act [3]. Group 3: Company Overview - Ryman Hospitality Properties, Inc. is a leading real estate investment trust specializing in upscale convention center resorts and entertainment experiences, managing a portfolio that includes five of the top seven largest non-gaming convention center hotels in the U.S. [5]. - The company owns a total of 12,364 hotel rooms and over 3 million square feet of meeting space across its properties [5]. - Ryman also holds a 70% controlling interest in Opry Entertainment Group, which includes iconic country music brands and manages various entertainment venues [5].

Core Viewpoint - Virtuix Inc. is advancing the field of full-body virtual reality systems through its Omni technology, which allows for natural movement in AI-generated environments, enhancing human-robot interaction and teleoperation capabilities [1][2][5]. Group 1: Collaboration and Technology - Virtuix has partnered with the University of Central Florida's Institute for Simulation & Training to demonstrate real-time control of humanoid robots using the Omni One omni-directional treadmill [2][4]. - The Omni One system enables operators to walk and move in any direction, allowing humanoid robots to mirror these movements, addressing limitations in teleoperation [4][5]. - The collaboration utilizes a stereoscopic "CAVE-like" projection system called vDen, which enhances operator comfort and spatial awareness without the need for head-mounted displays [5][6]. Group 2: Product Development - Virtuix is collaborating with 1HMX to develop the Nexus NX1, a full-body system designed for humanoid robot teleoperation and physical AI training [7]. - The NX1 integrates the Omni One treadmill with HaptX Gloves G1, providing lifelike tactile feedback and real-time sensory data to improve robot performance [7][8]. - This system aims to generate detailed movement data that can enhance the autonomy and capabilities of humanoid robots [8]. Group 3: Market Position and Vision - Virtuix positions itself as a leader in the full-body virtual reality market, catering to consumer, enterprise, and defense sectors with its innovative Omni technology [9]. - The company emphasizes the potential of its products in the growing field of humanoid robots and embodied AI, highlighting the importance of immersive VR technology in practical robotics applications [5][6].

Core Insights - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for various CNS disorders, including Alzheimer's disease and Parkinson's disease [1][3] - The company will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 [1] Company Overview - Anavex Life Sciences Corp. is publicly traded on Nasdaq under the ticker AVXL and is dedicated to developing novel therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders [3] - The lead drug candidate, ANAVEX2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and has shown potential in treating Parkinson's disease dementia and Rett syndrome [3] - ANAVEX2-73 is designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, with preclinical studies indicating its ability to halt or reverse Alzheimer's disease progression [3] - The company is also developing ANAVEX3-71, which targets SIGMAR1 and M1 muscarinic receptors, showing promise in addressing cognitive deficits and other hallmarks of Alzheimer's disease in preclinical trials [3]

Core Insights - Plus Therapeutics has received approval for a new Category III CPT code from the American Medical Association to track the utilization of convection-enhanced delivery (CED) for REYOBIQ therapy in recurrent glioblastoma and pediatric brain cancer, marking a significant step towards market access and commercialization [1][2] Group 1: REYOBIQ Therapy - REYOBIQ (rhenium Re186 obisbemeda) is a novel injectable radiotherapy designed to deliver targeted high-dose radiation to CNS tumors, potentially improving patient outcomes compared to existing therapies [3] - The therapy is currently being evaluated in clinical trials for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer, with significant funding support from various institutions, including a $17.6 million grant from the Cancer Prevention & Research Institute of Texas [3] Group 2: Market Access and Utilization Tracking - The approved Category III CPT code, X566T, will facilitate the tracking of CED procedures for REYOBIQ, aiding in the evaluation of its clinical use and supporting future reimbursement and coverage decisions [2] - The new CPT code will be published on July 1, 2026, and will take effect for reporting on January 1, 2027, which is expected to enhance the adoption of REYOBIQ in clinical settings [2] Group 3: Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for challenging CNS cancers, aiming to improve clinical outcomes through innovative treatment approaches [4] - The company has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [4]

MONTRÉAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V NBY) (OTCQB: NBYCF), is proud to provide a new resource estimate (the “2026 MRE”) for the Crevier niobium (Nb) and tantalum (Ta) project (the “Crevier Project”), which is 72.5% owned by NioBay and 27.5 % by Niobec (a subsidiary of Magris Performance Materials Inc.). The Crevier Project is located approximately 50 km north of the town of Girardville and approximately 150 km from the Niobec mine. It lies within t ...

Crystal Works Agreement Drives South Asia Adoption of Wrap’s Integrated Non-Lethal Response and Training EcosystemMIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Wrap Technologies, Inc. (NASDAQ: WRAP) (“Wrap” or the “Company”), a global leader in non-lethal response and public safety technology, today announced a strategic distribution agreement with Crystal Works Private Limited (“Crystal Works”), a premier supplier of advanced technology solutions for defense and law enforcement markets in India. The agreement i ...

– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES – Vancouver, BC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF), a publicly traded investment issuer focused on building and accelerating a portfolio of pioneering companies in the humanoid robotics and embodied AI sector, is pleased to announce its capital deployment strategy outlook for 2026. Humanoid Global intends to pursue a strategic ac ...

LOUISVILLE, Ky., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Stock Yards Bancorp, Inc. (NASDAQ: SYBT), parent company of Stock Yards Bank & Trust Company, with offices in the Louisville, central, eastern and northern Kentucky, as well as the Indianapolis, Indiana and Cincinnati, Ohio metropolitan markets, announced that its Board of Directors has declared a quarterly cash dividend of $0.32 per common share. The dividend will be paid on April 1, 2026, to stockholders of record as of March 16, 2026. Louisville, Kentuck ...